Completed
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
NCT02898116
- Conditions
- Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +12 more
- Locations
-
- Research Facility New York, United States